WO2001051118A2 - Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee - Google Patents

Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee Download PDF

Info

Publication number
WO2001051118A2
WO2001051118A2 PCT/US2001/000416 US0100416W WO0151118A2 WO 2001051118 A2 WO2001051118 A2 WO 2001051118A2 US 0100416 W US0100416 W US 0100416W WO 0151118 A2 WO0151118 A2 WO 0151118A2
Authority
WO
WIPO (PCT)
Prior art keywords
stimulation
select
shoulder
pulse train
muscle tissue
Prior art date
Application number
PCT/US2001/000416
Other languages
English (en)
Other versions
WO2001051118A3 (fr
Inventor
John Chae
David Yu
Zi-Ping Fang
Maria Walker
Original Assignee
Neurocontrol Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocontrol Corporation filed Critical Neurocontrol Corporation
Priority to AU29294/01A priority Critical patent/AU2929401A/en
Priority to EP01942314A priority patent/EP1251903A2/fr
Publication of WO2001051118A2 publication Critical patent/WO2001051118A2/fr
Publication of WO2001051118A3 publication Critical patent/WO2001051118A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36003—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of motor muscles, e.g. for walking assistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode

Definitions

  • the present invention relates to the art of therapeutic neuromuscular stimulation. It finds particular application for use by human patients who are paralyzed or partially paralyzed due to cerebrovascular accidents such as stroke or the like.
  • the invention is useful for retarding, preventing muscle disuse atrophy and even improving muscular condition, maintaining or improving extremity range- of-motion, facilitating voluntary motor function, relaxing spastic muscles, and increasing blood flow to select muscles of the shoulder. Additional benefits of the invention may include improved alignment and decreased pain.
  • the invention is particularly useful for the treatment of shoulder dysfunction.
  • An estimated 555,000 persons are disabled each year in the United States of America by cerebrovascular accidents (CVA) such as stroke.
  • CVA cerebrovascular accidents
  • Many of these patients are left with partial or complete paralysis of an extremity including for example, hemiplegic subluxation (incomplete dislocation) of the shoulder joint.
  • This is a common occurrence and has been associated with chronic and debilitating pain among stroke survivors.
  • motor recovery is frequently poor and rehabilitation is impaired.
  • rehabilitation is impaired.
  • the patient may not achieve his/her maximum functional potential and independence. Therefore, prevention and treatment of subluxation in stroke patients is a priority.
  • transcutaneous electrical muscular stimulation has been used therapeutically for the treatment of shoulder subluxation and associated pain, as well as for other therapeutic uses.
  • Therapeutic transcutaneous stimulation has not been widely accepted in general because of stimulation-induced pain and discomfort, poor muscles selectivity, and difficulty in daily management of electrodes, which necessitates a highly specialized clinician for treatment.
  • commercially available stimulators are relatively bulky, have high-energy consumption, and use cumbersome connecting wires.
  • transcutaneous stimulation systems are typically limited to two stimulation output channels.
  • the electrodes mounted on the surface of the patient's skin are not able .to select muscles to be stimulated with sufficient particularity and are not suitable for stimulation of the deeper muscle tissue of the patient as required for effective therapy. Any attempt to use greater than two surface electrodes on a particular region of a patient's body is likely to result in suboptimal stimulation due to poor muscle selection. Further, transcutaneous muscle stimulation via surface electrodes commonly induces pain and discomfort.
  • a therapy involves therapeutic electrical stimulation of select shoulder muscles of a patient.
  • the therapy includes the implantation of a plurality of intramuscular stimulation electrodes directly into selected shoulder muscles of a patient near the muscle motor point. This avoids stimulation of cutaneous nociceptors; requires lower stimulus intensities and avoids uncomfortable stimulation of adjacent non-target muscles.
  • the electrodes are addressed using an external battery-operated, microprocessor-based stimulation pulse train generator, which generates select electrical stimulation pulse train signals.
  • the pulse train generator is portable and in particular is miniaturized to a convenient size.
  • This pulse train generator includes a plurality of electrical stimulation pulse train output channels connected respectively to the plurality of percutaneous electrode leads. Stimulation pulse train parameters are selected for each of the stimulation pulse train output channels independently of the other channels. Muscle selection was determined generally by three-dimensional radiographic evaluation of a number of patients along with selective stimulation of all of the shoulder muscles.
  • a preferred therapy involved asynchronous stimulation of more than one muscle group and more preferably with a first muscle group being the supraspinstus in combination with the middle deltoid and a second muscle group being the trapezious in combination with the posterior deltoid.
  • the stimulation pulse train parameters or regiment or dosage include at least pulse amplitude and pulse width or duration for stimulation pulses of the stimulation pulse train, and an interpulse interval between successive pulses of the stimulation pulse train defining a pulse frequency.
  • the therapy involves the asynchronous stimulation of more than one muscle or muscle group. This asynchronous stimulation involves intermittent periods of stimulation and rest with different pulse train envelop delivered to the multiple sites but not in a synchronized dose.
  • one muscle or muscle group may be resting while another muscle or muscle group may be subjected to stimulation.
  • these two dosages are the same but offset in time.
  • more than one stimulation cycle is delivered at a point in time so that a first cycle may be delivered to a first muscle or muscle group with a second muscle or group undergoing a second stimulation cycle (which can be a straight, low-level stimulation or a cycle having a different profile, or can be the same cycle applied at a different point in time).
  • the electrical stimulators include means for generating stimulation pulse train signals with the selected pulse train parameters on each of the plurality of stimulation pulse train output channels so that stimulus pulses of the pulse train signals having the select stimulation pulse train parameters pass between the intramuscular electrodes respectively connected to the stimulation pulse train output channels and a reference electrode.
  • a method of stimulating select shoulder muscle tissue of a patient includes programming a patient external stimulation pulse generator with at least one stimulation pulse train session including at least one stimulation cycle (and preferably at least two stimulation cycles) defining a stimulation pulse train envelope for a plurality of stimulation pulse train output channels.
  • Each envelope is defined by at least a ramp-up phase of a first select duration wherein pulses of a stimulus pulse train progressively increase in charge, a hold phase of a second select duration wherein pulses of the stimulus pulse train are substantially constant charge, and a ramp-down phase of a third select duration wherein pulses of the stimulus pulse train progressively decrease in charge.
  • a second hold phase there is no stimulus delivered and the muscles are allowed to relax or rest.
  • two muscle groups are subjected to a first and a second stimulation cycles so that one set of muscles is stimulated during the rest cycle of the second set of muscles. This inhibits the shoulder from slipping back into misalignment during the rest portion of the cycle.
  • a plurality of intramuscular electrodes are implanted into select shoulder muscle tissue of the patient and electrically connected by percutaneous electrode leads to the plurality of output channels, respectively, of the pulse train generator.
  • stimulation pulse train signals are generated with the generator so that the select muscle tissue of the patient is stimulated in accordance with the at least one stimulation cycle.
  • one advantage of the present invention is the provision of a therapeutic percutaneous intramuscular stimulation system that retards or prevents muscle disuse atrophy, maintains muscle range-of-motion, facilitates voluntary motor function, relaxes spastic muscles, and increases blood flow in selected muscles.
  • Another advantage of the present invention is that it provides a therapeutic muscular stimulation system that uses intramuscular, rather than skin surface (transcutaneous) electrodes to effect muscle stimulation of select shoulder muscles.
  • the treatment dosage or regiment, which is prescribed may be tailored to suit individual needs and selectively varied even during the course of treatment. For example, the stimulus may be titrated at the onset to avoid pain and unwanted joint movement (such as for example, active elbow flexion during biceps stimulation).
  • a method of therapy for treatment of shoulder dysfunction (such as subluxation) which comprises the steps of: 1 ) radiographic evaluation of the shoulder- in at least two planes (preferably the subluxation is evaluated in 3- dimentisons); 2) percutaneous implantation of two or more electrodes, so as to contact a muscle or nerve, the electrode being in electrical communication with a pulse train generator; and 3) actuation of the pulse train generator in accordance with a regiment or prescribed dosage to cause stimulation of the muscle or nerve using the electrodes.
  • the regiment or course of treatment may be a pre-defined course of treatment based on a stimulation pattern, which has been stored in a host computer or integral microprocessor, which can be used to address the pulse train generator.
  • the regiment will include individual sessions having a ramped profile and including intermittent stimulation activation of the electrode or electrodes with periods of rest.
  • the treatment of shoulder subluxation involves implantation of one or more electrodes into the superspinatus as well as into the posterior, middle and anterior deltoids; into the coracolbrachialis; into the biceps and triceps longhead. Even more preferably the treatment accounts for shoulder relocation in three dimensions with a focus on stimulation of all heads of the deltoid, the coracobrachialis, the biceps and the triceps longhead. Modulation of the stimulus may require precise muscle activation to balance against agonist and antagonist activity to avoid undesirable joint translation and rotation.
  • FIGURE 1 A is a front elevational view of a portable, programmable stimulation pulse train generator in accordance with the present invention
  • FIGURE 1 B - 1 D are top, bottom, and right-side elevational views of the stimulation pulse train generator of FIGURE 1 A;
  • FIGURE 2 illustrates a preferred intramuscular electrode and percutaneous electrode lead
  • FIGURE 3 graphically illustrates the stimulation paradigm of the percutaneous intramuscular stimulation system in accordance with the present invention.
  • FIGURE 4 graphically illustrates the preferred stimulation paradigm
  • FIGURE 5 is a graphic illustration of the results of the study of Example 1 ;
  • FIGURE 6 is a second graphic illustration of the results of the study of Example 1 ;
  • FIGURE 7 is a graphic illustration of the results of the study of Example 2
  • FIGURE 8 is a second graphic illustration of the results of the study of Example 2;
  • FIGURE 9 is a third graphic illustration of the results of the study of Example 2.
  • FIGURE 10 is a fourth graphic illustration of the results of the study of Example 2; and -7-
  • FIGURE 12 is a sixth graphic illustration of the results of the study of Example 2.
  • the stimulator includes an electrical stimulation pulse generator 10.
  • the pulse generator 10 includes a lightweight, durable plastic housing 1 2 fabricated from a suitable plastic or the like.
  • the case 1 2 includes a clip
  • the case 12 also includes a releasable battery access cover 16.
  • a visual display 20 For output of visual data to a patient or clinician operating the stimulation system, a visual display 20 is provided.
  • the display 20 is preferably provided by a liquid crystal display, but any other suitable display means may alternatively be used.
  • An audio output device, such as a beeper 22 is also provided.
  • the stimulation pulse generator 10 includes means for input of data.
  • the pulse generator 10 includes an increment switch 24, a decrement switch 26, and a select or "enter” switch 28.
  • the increment and decrement switches 24, 26 are used to cycle through operational modes or patterns and stimulation parameters displayed on the display 20, while the select switch 28 is used to select a particular displayed operational pattern or stimulation parameter.
  • the select switch 28 also acts as a power on/off toggle switch.
  • the pulse train generator 10 For output of electrical stimulation pulse train signals, the pulse train generator 10 includes an external connection socket 30 that mates with a connector of an electrode cable assembly (not shown) to interconnect the pulse generator 10 with a plurality of intramuscular -8-
  • the cable assembly connected to the socket 30 includes a second connector on a distal end that mates with a connector attached to the proximal end of each of the percutaneous stimulation electrode leads and a reference electrode lead.
  • the electrode lead 40 is fabricated from a 7-strand stainless steel wire insulated with a biocompatible polymer. Each individual wire strand has a diameter of 34 ⁇ m and the insulated multi- strand lead wire has a diameter of 250 ⁇ m.
  • the insulated wire is formed into a spiral or helix as has been found preferred to accommodate high dynamic stress upon muscle flexion and extension, while simultaneously retaining low susceptibility to fatigue.
  • the outer diameter of the helically formed electrode lead 40 is approximately 580 ⁇ m and it may be encased or filled with silicone or the like.
  • a proximal end 44 of each of the plurality of intramuscular electrode lead wires 40 are located exterior to the patient's body when in use.
  • the proximal end 44 includes a deinsulated length for connection to an electrical connector in combination with the remainder of the electrode leads.
  • the distal end 46 of each lead 40 which is inserted directly into muscle tissue, also includes a deinsulated length, which acts as the stimulation electrode 50. It is preferred that at least a portion of the deinsulated length be bent or otherwise deformed into a barb 48 to anchor the electrode in the selected muscle tissue.
  • a taper 52 made from silicone adhesive or the like, is formed between the deinsulated distal end 50 and the insulated portion of the lead 40 to reduce stress concentration.
  • each of the plurality of percutaneous electrodes 50 is surgically implanted or inserted into select patient shoulder, arm, or upper-trunk muscle tissue, and the associated electrode lead 40 exits the patient percutaneously, i.e., through the skin, for connection to the stimulation pulse generator 10.
  • each of the electrodes 50 is implanted or inserted into the select muscles by use of a hypodermic needle.
  • muscles may be surgically exposed for implantation or minimally invasive techniques such as arthroscopy may be used.
  • the present percutaneous, intramuscular stimulation system allows for precise muscle selection and use of three or more stimulation electrodes and channels.
  • the preferred system in accordance with the present invention uses up to eight or more intramuscular electrodes 50, each connected to an independent electrode stimulation channel E, and a single reference electrode 52 which may be either an intramuscular or surface electrode.
  • the stimulation pulse generator 10 comprises a microprocessor- based stimulation pulse generator circuit with a micro controller such as a Motorola 68HC12. Operational instructions or other information are stored in non-volatile storage. Set stimulation therapy or patterns may be included in this storage. These therapies may be based upon generalized information such as may be gathered from radiographic evaluation in multiple dimensions along with selected stimulation. Ultimately patient specific information may be incorporated into the stimulation parameters in order to optimize the therapy for a particular individual application.
  • the nonvolatile memory also provides -10-
  • a real time clock is provided as part of the circuit.
  • the electrical stimulator current passes between the selected electrodes and the reference electrode.
  • a pulse duration timer provides timing input PDC as determined by the CPU to the pulse amplitude/duration controller to control the duration of each stimulation pulse.
  • the CPU provides a pulse amplitude control signal to the circuit by way of the serial peripheral interface to control the amplitude of each stimulation pulse.
  • One suitable circuit means for output of stimulation pulses as described above is in accordance with that described in U.S. Patent 5, 1 67,229, the disclosure of which is hereby expressly incorporated by reference.
  • An impedance detection circuit is used to monitor the therapy.
  • Each output channel E1-E8 includes independent electrical charge storage means such as a capacitor SC which, is charged to the high voltage V H through a respective current limiting diode CD.
  • the microcontroller output circuit 102 provides channel select input data to switch component, as to the particular channel E1 - E8 on which the pulse is to be passed. Switch means SW closes the selected switch accordingly.
  • the microcontroller also provides a pulse amplitude control signal PAC into a voltage-controlled current source VCCS.
  • the pulse amplitude control signal PAC controls the magnitude of the current I
  • the circuit VCCS ensures that the current I is constant at that select level as dictated by the pulse amplitude control input PAC.
  • the current I be within an approximate range of 1 mA - 20mA.
  • the discharged capacitor SC Upon completion of the cathodic phase Q c as controlled by the pulse duration control signal PDC, the discharged capacitor SC recharges upon opening of the formerly closed one of the switches SW, - SW 8 . -11-
  • the flow of recharging current to the capacitor SC results in a reverse current flow between the relevant electrode 50 and the reference electrode 52, thus defining an anodic pulse phase Q a .
  • the current amplitude in the anodic pulse phase Q a is limited, preferably to 0.5mA, by the current limiting diodes CD.
  • the duration of the anodic phase is determined by the charging time of the capacitor SC, and current flow is blocked upon the capacitor becoming fully charged. It should be recognized that the interval between successive pulses or pulse frequency PF is controlled by the CPU 62 directly through output of the channel select, pulse amplitude, and pulse duration control signals as described at a desired frequency PF.
  • a preferred design implements from 2 to 8 or more independent preprogrammed patterns.
  • a stimulation session S is pre-programmed into the stimulator circuit by a clinician through use of the input means.
  • Each session S has a maximum session duration of approximately 9 hours, and a session starting delay D.
  • the maximum session starting delay D is approximately 1 hour.
  • the session starting delay D allows a patient to select automatic stimulation session start at some future time.
  • a plurality of stimulation cycles C are programmed for stimulation of selected muscles.
  • each stimulation cycle ranges from 2-100 seconds in duration.
  • a stimulus pulse train T includes a plurality of successive stimulus pulses P.
  • each stimulus pulse P is current-regulated and diphasic, i.e., comprises a cathodic charge phase Q c and an anodic charge-phase Q a .
  • the magnitude of the cathodic charge phase Q c is equal to the magnitude of the anodic charge phase Q a .
  • the current-regulated, biphasic pulses P provide for consistent -12-
  • Each pulse P is defined by an adjustable pulse amplitude PA and an adjustable pulse duration PD.
  • the pulse frequency PF is also adjustable. Further, the pulse amplitude PA, pulse duration PD, and pulse frequency PF are independently adjustable for each stimulation channel E.
  • the amplitude of the anodic charge phase Q a is preferably fixed ,at 0.5mA, but may be adjusted if desired.
  • Pulse “ramping” is used at the beginning and end of each stimulation pulse train T to generate smooth muscle contraction.
  • Ramping is defined herein as the gradual change in cathodic pulse charge magnitude by varying at least one of the pulse amplitude PA and pulse duration PD.
  • FIGURE 3 the preferred ramping configuration is illustrated in greater detail.
  • each of the plurality of stimulation leads/electrodes 40,50 is connected to the pulse generator circuit 60 via a stimulation pulse channel E.
  • eight stimulation pulse channels E1 ,E2,E8 are provided to independently drive up to eight intramuscular electrodes 50.
  • Stimulation pulse trains transmitted on each channel E1 -E8 are transmitted within or in accordance with a stimulation pulse train envelope B1 -B8, respectively.
  • each envelope B1 -B8 is independently adjustable by a clinician for each channel E1 -E8.
  • each envelope B1 -B8 is defined by a delay or "off" phase PD 0 where no pulses are delivered to the electrode connected to the subject channel, i.e., the pulses have a pulse duration
  • the pulse duration PD of each pulse P is increased or "ramped-up" over time during a "ramp-up" phase PD, from a minimum value (e.g., 5 ⁇ sec) to a programmed maximum value.
  • a pulse duration "hold” phase PD 2 the pulse duration PD remains constant -13-
  • pulse duration PD of each pulse P is decreased over time to lessen the charge delivered to the electrode 50.
  • This "ramping-up” and “ramping-down” is illustrated even further with reference to the stimulation pulse train T which is provided in correspondence with the envelope B8 of the channel E8.
  • the pulse P of the pulse train T first gradually increase in pulse duration PD, then maintain the maximum pulse duration PD for a select duration, and finally gradually decrease in pulse duration PD.
  • the pulse amplitude PA, pulse duration PD, pulse frequency PF, and envelope B1 -B8 are user-adjustable for every stimulation channel E, independently of the other channels.
  • the stimulation pulse generator circuit 60 is pre-programmed with up to four stimulation patterns, which will allow a patient to select the prescribed one of the patterns as required during therapy.
  • the pulse generator 1 0 includes at least up to eight stimulation pulse channels E.
  • the stimulation pulse trains T of each channel E are sequentially or substantially simultaneously transmitted to their respective electrodes 50.
  • the pulse frequency PF is preferably adjustable within the range of approximately 5Hz to approximately 50Hz;
  • the cathodic amplitude PA is preferably adjustable within the range of approximately 1 mA to approximately 20mA;
  • the pulse duration PD is preferably adjustable in the range of approximately 5 ⁇ sec to approximately 200 ⁇ sec, for a maximum of approximately 250 pulses per second delivered by the circuit 60.
  • Figure 4 illustrates an asynchronous stimulation profile consisting of a first stimulation cycle 10 administered to a first muscle group, i.e. the posterior deltoid and the supraspinatus, and a second stimulation cycle 20 which has the same stimulation profile but is offset from the -14-
  • a method of therapy for treatment of shoulder dysfunction (such as subluxation) which comprises the steps of: 1 ) percutaneous implantation of two or more electrodes, so as to contact a muscle or nerve, the electrode being in electrical communication with a pulse train generator; and 2) actuation of the pulse train generator in accordance with a regiment or prescribed dosage to cause stimulation of the muscle or nerve using the electrodes which dosage has been defined as a result of a radiographic evaluation in three-dimensions (i.e.
  • the regiment or course of treatment may be a pre-defined course of treatment based on a stimulation pattern, which has been stored in a host computer or integral microprocessor, which can be used to address the pulse train generator.
  • the regiment will include individual sessions having a ramped profile and including intermittent stimulation activation of the electrode or electrodes with periods of rest.
  • the treatment of shoulder subluxation involves implantation of one or more electrodes into the superspinatus as well as into the posterior, middle and anterior deltoids; into the coracolbrachialis; into the biceps and triceps longhead.
  • the treatment accounts for shoulder relocation in three dimensions with a focus, on stimulation of all heads of the deltoid, the coracobrachialis, the biceps and the triceps longhead. Modulation of the stimulus may require precise muscle activation to balance against agonist and antagonist activity to avoid undesirable joint translation and rotation.
  • the preferred treatment regiment is illustrated in FIGURE 4 and thus therapy involves two stimulation cycles applied asynchronously. -15-
  • Each cycle has a 30 + 10 seconds period with 3-8; preferably 5 ⁇ 1 seconds each of ramp on and off and 5-1 5, preferably 10 + 2 seconds of hold.
  • One cycle is applied to the posterior deltoid in combination with the supraspinatus while the other cycle is applied at a 5 ⁇ 5 second offset to the middle deltoid in combination with the upper trapezoidious.
  • the cycle utilizes a balanced charge wave-form meaning that each pulse has an equal amount of positive and negative charge in each pulse.
  • the envelope illustrates the outline of the amplitude of multiple pulses.
  • the treatment generally involves weekly to daily periods of treatment for several minutes up to several hours.
  • One postulated treatment involves
  • the pulse train generator is miniature so that it is easily portable. Further, it provides multiple channels to allow a therapy or treatment use involving multiple nerves and/or multiple muscles. It is envisioned that the method of the present invention may have use in the treatment of acute and/or chronic dysfunction including the treatment of pain. For the treatment of shoulder dysfunction in hemiplegics .(i.e., one sided paralysis) the therapy may even begin immediately upon presentation of stroke symptoms as a prophalalic treatment with respect to shoulder subluxation.
  • the treatment is envisioned for indications involving dysfunction of the central nervous systems including stroke or traumatic brain injury, spinal cord injury, cerebral palsy and other condition, which result in debilitation of the nervous system.
  • the treatment may incorporate continuous stimulation for some period of time such as four to eight, or around six hours per day. Since the therapy is passive and relatively free from pain, the patient may undergo treatment while otherwise conducting life as usual. -16-
  • the first study compared the level of discomfort associated with intramuscular and transcutaneous NMES during reduction of shoulder subluxation.
  • the second study was a pilot study investigating the effects of percutaneous, intramuscular NMES on shoulder subluxation, range of motion, pain, motor recovery and disability in persons with chronic hemiplegia and shoulder subluxation.
  • the third study was a preliminary study to determine whether the muscles previously selected in the transcutaneous NMES studies are, in fact, the muscles which provide maximal reduction of shoulder subluxation.
  • EXAMPLE 1 To compare stimulation-induced pain between transcutaneous and percutaneous, intramuscular NMES, 10 subjects were enrolled with hemiplegia and at least one fingerbreadth of shoulder subluxation. A cross over study design was used. Each subject received 3 pairs of randomly ordered transcutaneous or intramuscular stimulation. Both types of stimulation were modulated to provide full joint reduction by palpation with the least discomfort. Subjects were blinded to the type of stimulation given. The evaluator was blinded to the type of stimulation given when assessing joint reduction by palpation and when administering the pain measures. Pain was measured using a 10 cm visual analogue scale and the McGill Pain Questionnaire using the pain rating index (PRI) method for quantification of data. The pain descriptors of the McGill Pain Questionnaire were read aloud to subjects during each administration. Pain measures were obtained immediately after each of the six stimulations. After the last pair of stimulations, the subjects were -17-
  • T1 intramuscular NMES
  • T2 intramuscular NMES
  • T3 3 month follow-up
  • the self-care portion of the FIM was not a good choice for measurement of disability in this population because the self-care tasks can be performed independently with a single intact upper limb.
  • improvements in FIM scores may not be due to motor recovery and did not parallel changes in FMS.
  • the improved FIM scores may -19-
  • EXAMPLE 3 The third study determined whether the standard muscles targeted for stimulation provide the best reduction of shoulder subluxation.
  • the supraspinatus and posterior deltoid muscles were stimulated in the previously discussed transcutaneous NMES studies. These muscles were selected based on a study by Basmajian et al. In his study, EMG activity in the shoulder muscles of normal adults were observed during rest and inferiorly directed traction on the upper limb. The supraspinatus was found to be uniformly active and the posterior deltoid less active under these conditions. In our pilot experience with intramuscular NMES for treating shoulder subluxation, the supraspinatus did not consistently reduce subluxation during stimulation. A preliminary survey of various shoulder muscles was undertaken to determine whether other muscles may provide better joint reduction during stimulation.
  • joint reduction was assessed by palpation in all subjects and radiographically in two subjects using a three-dimensional technique that standardizes trunk and limb position, uses the glenoid fossa as a reference frame and measures the difference in joint translation between the affected and unaffected shoulders. Stimulation of the supraspinatus muscle provided incomplete reduction of subluxation. Several other muscles provided more complete and more consistent joint reduction including all heads of the deltoid, the coracobrachialis, the biceps and the triceps long head. While radiographic inferior subluxation correlated well with palpation, the three-dimensional technique correlated poorly with subluxation measured by palpation. This discrepancy was felt to be due to inadequate assessment of anterior subluxation by palpation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Electrotherapy Devices (AREA)
  • Magnetic Treatment Devices (AREA)

Abstract

L'invention concerne une méthode de traitement d'un dysfonctionnement de l'épaule, comprenant l'utilisation d'un système de stimulation intramusculaire percutanée. Selon l'invention, une pluralité d'électrodes de stimulation intramusculaire est implantée directement dans des muscles sélectionnés de l'épaule d'un patient atteint d'un dérèglement du système nerveux central tel qu'un accident cérébro-vasculaire, un traumatisme cérébral, un traumatisme médullaire ou une infirmité motrice cérébrale. Un générateur de trains d'impulsions de stimulation multicanal basé sur un microprocesseur extérieur est utilisé pour générer des signaux de trains d'impulsions de stimulation électrique sélectionnés. Une pluralité de tiges d'électrodes isolées relient électriquement à travers la peau respectivement la pluralité des électrodes de stimulation intramusculaire au générateur de trains d'impulsions de stimulation extérieur. Des paramètres de trains d'impulsions de stimulation pour chacun des canaux de sortie de trains d'impulsions de stimulation sont sélectionnés indépendamment des autres canaux. Le diagnostic de l'épaule est une subluxation dans plus d'une dimension. Plus d'un muscle ou plus d'un groupe musculaire sont simultanément soumis à une dose de trains d'impulsions. Les deux doses minimales sont de préférence délivrées de manière asynchrone à deux groupes musculaires comprenant le sus-épineux en combinaison avec le deltoïde médian, et le trapèze en combinaison avec le deltoïde postérieur.
PCT/US2001/000416 2000-01-07 2001-01-06 Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee WO2001051118A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29294/01A AU2929401A (en) 2000-01-07 2001-01-06 Treatment of shoulder dysfunction using a percutaneous intramuscular stimulationsystem
EP01942314A EP1251903A2 (fr) 2000-01-07 2001-01-06 Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17488600P 2000-01-07 2000-01-07
US60/174,886 2000-01-07

Publications (2)

Publication Number Publication Date
WO2001051118A2 true WO2001051118A2 (fr) 2001-07-19
WO2001051118A3 WO2001051118A3 (fr) 2002-01-31

Family

ID=22637941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000416 WO2001051118A2 (fr) 2000-01-07 2001-01-06 Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee

Country Status (3)

Country Link
EP (1) EP1251903A2 (fr)
AU (1) AU2929401A (fr)
WO (1) WO2001051118A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090844A2 (fr) * 2002-04-26 2003-11-06 Medtronic, Inc. Mise en forme d'une onde pour un dispositif medical implantable
US9669226B2 (en) 2010-09-07 2017-06-06 Empi, Inc. Methods and systems for reducing interference in stimulation treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026301A (en) * 1975-04-21 1977-05-31 Medtronic, Inc. Apparatus and method for optimum electrode placement in the treatment of disease syndromes such as spinal curvature
US4326534A (en) * 1979-06-21 1982-04-27 Jens Axelgaard Transcutaneous electrical muscle stimulation for treatment of scoliosis and other spinal deformities
US4595010A (en) * 1984-03-12 1986-06-17 Bio-Research Associates, Inc. Electrical muscle stimulator
US5702428A (en) * 1992-05-23 1997-12-30 Axelgaard Manufacturing Company, Ltd. Electrical stimulation for treatment of incontinence and other neuro-muscular disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026301A (en) * 1975-04-21 1977-05-31 Medtronic, Inc. Apparatus and method for optimum electrode placement in the treatment of disease syndromes such as spinal curvature
US4326534A (en) * 1979-06-21 1982-04-27 Jens Axelgaard Transcutaneous electrical muscle stimulation for treatment of scoliosis and other spinal deformities
US4595010A (en) * 1984-03-12 1986-06-17 Bio-Research Associates, Inc. Electrical muscle stimulator
US5702428A (en) * 1992-05-23 1997-12-30 Axelgaard Manufacturing Company, Ltd. Electrical stimulation for treatment of incontinence and other neuro-muscular disorders

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090844A2 (fr) * 2002-04-26 2003-11-06 Medtronic, Inc. Mise en forme d'une onde pour un dispositif medical implantable
WO2003090844A3 (fr) * 2002-04-26 2004-04-01 Medtronic Inc Mise en forme d'une onde pour un dispositif medical implantable
US9669226B2 (en) 2010-09-07 2017-06-06 Empi, Inc. Methods and systems for reducing interference in stimulation treatment
US11065454B2 (en) 2010-09-07 2021-07-20 Djo, Llc Methods and systems for reducing interference in stimulation treatment
US11794019B2 (en) 2010-09-07 2023-10-24 Djo, Llc Methods and systems for reducing interference in stimulation treatment

Also Published As

Publication number Publication date
EP1251903A2 (fr) 2002-10-30
AU2929401A (en) 2001-07-24
WO2001051118A3 (fr) 2002-01-31

Similar Documents

Publication Publication Date Title
US6845271B2 (en) Treatment of shoulder dysfunction using a percutaneous intramuscular stimulation system
Inanici et al. Transcutaneous spinal cord stimulation restores hand and arm function after spinal cord injury
US20210106829A1 (en) Systems and methods for the treatment of pain through neural fiber stimulation
US20220288394A1 (en) Systems and methods for the treatment of pain through neural fiber stimulation
Takeda et al. Review of devices used in neuromuscular electrical stimulation for stroke rehabilitation
Malešević et al. Distributed low‐frequency functional electrical stimulation delays muscle fatigue compared to conventional stimulation
US9254382B2 (en) Apparatus for transcutaneous electrical stimulation of the tibial nerve
US10076663B2 (en) Systems and methods for the treatment of pain through neural fiber stimulation
Hallett et al. Magnetism: a new method for stimulation of nerve and brain
US11433238B2 (en) Treatment of phantom limb pain and diabetic neuropathy pain, and increasing prosthetic control, by stimulation of dorsal rootlets and lateral spinal cord
JP2021534877A (ja) 神経根麻痺、馬尾症候群、及び上肢機能の回復のための非侵襲性脊髄刺激
Zhang et al. Cervical spinal cord transcutaneous stimulation improves upper extremity and hand function in people with complete tetraplegia: a case study
US20060009816A1 (en) Percutaneous intramuscular stimulation system
Solomon et al. Safety and effectiveness of cranial electrotherapy in the treatment of tension headache
EP1251903A2 (fr) Traitement d'un dysfonctionnement de l'epaule en utilisant un systeme de stimulation intramusculaire percutanee
Balogun Effects of ramp time on sensory, motor and tolerance thresholds during exogenous electrical
Elboim‐Gabyzon et al. Effects of interphase interval during neuromuscular electrical stimulation of the wrist extensors with maximally tolerated current intensity
Boucher Effectiveness of Surface Electromyographic Biofeedback-triggered Neuromuscular Electrical Stimulation on Quadriceps Femoris Torque and Recruitment
Convery et al. The effects of electrical stimulation and electromyographic biofeedback on muscle performance output with training of the quadriceps femoris muscle
Khorchai Using high-frequency EMG during PTR test and tSCS to develop and establish a measurement system for analysis of events chronology by healthy and individuals with spinal cord injury and the following treatment.
Drobitch et al. Modulation of Corticospinal Excitability Using Cathodal Transcranial Direct Current Stimulation to Improve Walking in Individuals with Chronic Post Stroke Hemiparesis
Venugopalan Restoration of hand and arm function to people with tetraplegia as a result of damage to the spinal cord in the neck through the use of functional electrical stimulation (FES).
Collins The influence of shoulder position on corticospinal excitability of the biceps brachii
Nguyen Multi-input transcutaneous neuromuscular electrical stimulation for control of the lower limb
Beekhuizen The effect of massed practice and somatosensory stimulation on upper extremity function and cortical plasticity in individuals with incomplete cervical spinal cord injury

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001942314

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001942314

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001942314

Country of ref document: EP